Peptides: Selank Overview

Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) developed at the Institute of Molecular Genetics in Moscow during the 1980s as a stable analogue of tuftsin. Tuftsin itself (Thr-Lys-Pro-Arg) is an endogenous tetrapeptide from IgG that modulates immune function and shows CNS activity, but is rapidly degraded by enzymatic cleavage. The Pro-Gly-Pro extension in Selank confers approximately 2-fold greater metabolic stability, extending its activity window after intranasal administration.

Selank is licensed in Russia as an anxiolytic and nootropic prescription drug. By Russian regulatory standards, evidence for approval is Grade B, based on controlled clinical trials conducted within Russian institutions. However, most of this trial data is published in Russian-language journals that are not indexed in PubMed or subjected to the same peer-review standards as Western journals. By Western evidence hierarchy standards, Selank is Grade C — evidence is primarily from rodent studies (PMID 19827524) and non-indexed clinical reports.

Pharmacological Effects

Effect	Mechanism	Evidence Level	Notes
Anxiolytic	GABA-A receptor sensitivity modulation; possible interaction with benzodiazepine site	B (Russian clinical); C (Western peer-review)	Licensed use in Russia; no Western RCTs
Nootropic/cognitive	BDNF upregulation; monoamine modulation	C	Rodent hippocampal data; PMID 19827524 (animal study)
BDNF upregulation	Increases hippocampal BDNF expression in rodents	C	Proposed mechanism for cognitive benefit; animal study only
Anti-inflammatory	Reduces pro-inflammatory cytokines in rodent models	C	IL-6, TNF-α reduction reported in animal studies
Immunomodulatory	Tuftsin-related immunostimulation; T-cell modulation	C	Derived from tuftsin lineage; not studied adequately in humans
Mood stabilization	Serotonin and dopamine system interactions	B (Russian clinical)	Reported in Russian clinical literature; hard to assess by Western standards

Dosing Reference

The standard Russian clinical formulation is a 0.15% nasal solution (1.5mg/mL), where 1 drop ≈ 25mcg. Typical dosing: 2–3 drops per nostril (50–75mcg per nostril) twice daily = 200–300mcg per dose. For subcutaneous research use, 250–500mcg per injection is the commonly cited range.

At doses above 500mcg/dose, no additional anxiolytic benefit has been reliably documented; higher doses do not appear to proportionally increase effect and may increase adverse reactions (mild sedation reported in some Russian case series).

Mechanism: GABA-A Modulation

Selank’s primary anxiolytic mechanism involves upregulating GABA-A receptor sensitivity — specifically enhancing the response to endogenous GABA rather than directly binding the receptor as benzodiazepines do. This distinction matters clinically: the mechanism is modulatory rather than substitutive, which may explain the absence of tolerance and withdrawal phenomena reported in Russian clinical practice. Serotonin transporter activity and dopamine metabolism are also affected, contributing to the reported mood-stabilizing and nootropic properties (PMID 19827524).

Legal Status

Jurisdiction	Status	Schedule	Notes
USA	Research chemical	Unscheduled	Not FDA-approved; no DEA schedule; legal to possess for research
UK	Not scheduled	None	No Medicines Act equivalent scheduling; legal to possess
Australia	Not specifically listed	Check TGA — no approved ARTG entry	No equivalent to a DIN; import for personal use in gray area
Canada	Gray market	No DIN	Health Canada has no approved product; import for personal use gray area
EU	Not harmonized	Varies by member state	No EMA approval; Russia: licensed prescription anxiolytic and nootropic

Evidence Caveat

It is important to interpret Selank’s evidence base carefully. Russian regulatory approval is real and meaningful within that system, but Russian clinical trial standards and publication norms differ substantially from those required for EMA or FDA approval. Western users should treat Selank evidence as Grade C for practical decision-making, acknowledging that Grade B data exists but in a form that cannot be fully evaluated by Western peer-review criteria.